C2N Diagnostics

• Philip Verghese

  Lead investigator

Sources: openalex.org

• BrightFocus Foundation

  Alzheimer's Disease Research: Other, SILK ABeta SPOT Test, CA2016636, US$750k, 2016–2018, 1 May 2016

Sources: openalex.org

• Plasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer Disease

  Employment, Fees or honoraria, Shares or equity, 12 Oct 2026

• A plasma-based protein signature combining NPTXR, ACHE, and p-tau217 predicts progression to symptomatic Alzheimer's disease

  Consulting or advice, Shares or equity, Founder, Board or leadership role, 1 Aug 2026

• Identification of distinct and shared biomarker panels in different manifestations of cerebral small-vessel disease through proteomic profiling

  Grants or research support, 24 Feb 2026

• The Knight Alzheimer Research Imaging (KARI) dataset: a comprehensive multimodal resource for exploring aging, preclinical, and symptomatic Alzheimer disease pathology

  Consulting or advice, Fees or honoraria, Board or leadership role, 7 Nov 2025

• Prospective Associations between Plasma Amyloid-Beta 42/40 and Frailty in Community-Dwelling Older Adults

  Consulting or advice, Shares or equity, Board or leadership role, 1 Jan 2021

Sources: pubmed.ncbi.nlm.nih.gov

• Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging

  Alzheimer's & dementia : the journal of the Alzheimer's Association, 7 Apr 2026

• Plasma Alzheimer's Disease Biomarker Associations with eGFR in Black and White Older Adults

  AAIC 2025 abstract, 9 Jan 2026

• Investigating Salivary Extracellular Vesicles as Biomarkers for Alzheimer's Disease: ExosomeAD Study Design and Baseline Characteristics

  AAIC 2025 abstract, 9 Jan 2026

• Age of plasma Aβ42/40 positivity in Black and White individuals

  AAIC 2025 abstract, 8 Jan 2026

• Comparison of Longitudinal Plasma Assays in Relation to Longitudinal Amyloid Pathology in Alzheimer's Disease

  AAIC 2025 abstract, 8 Jan 2026

• Associations between Digital Cognitive Assessment and Amyloid Burden in Cognitively Unimpaired Older Adults

  AAIC 2025 abstract, 26 Dec 2025

• The associations between major depressive disorder, plasma biomarkers of Alzheimer's disease, and mild behavior impairment among older adults

  AAIC 2025 abstract, 25 Dec 2025

• Cognitive Performance and Biomarker Profiles in Puipui Malu Manatu ( Preserving Memory ) ‐ a Population‐Based Prevalence Study ADRD in American Samoa

  AAIC 2025 abstract, 25 Dec 2025

• Detecting and monitoring longitudinal pathological and clinical changes of Alzheimer's disease using plasma p ‐Tau217

  AAIC 2025 abstract, 24 Dec 2025

• Association of Plasma Biomarkers of Alzheimer's Disease with Incident Tau PET Positivity

  AAIC 2025 abstract, 24 Dec 2025

• Comparison of Longitudinal Plasma Assays in Relation to Longitudinal Amyloid Pathology in Alzheimer’s Disease

  AAIC 2025 abstract, 23 Dec 2025

• Streamlining Recruitment for AD Clinical Trials: Concurrent Detection of Cognitive Impairment and Amyloid‐Beta PET Status with a Machine Learning‐Enabled Digital Cognitive Assessment

  AAIC 2025 abstract, 23 Dec 2025